Combination of rapamycin and IL-2 increases de novo induction of human CD4+CD25+FOXP3+ T cells

被引:57
作者
Long, S. Alice [1 ]
Buckner, Jane H. [1 ]
机构
[1] Benaroya Res Inst Virginia Mason, Dept Translat Res, Seattle, WA 98101 USA
关键词
FOXP3; IL-2; immune regulation; rapamycin; treg;
D O I
10.1016/j.jaut.2007.12.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immune system protects itself from autoreactivity by maintaining a balance between effector and Treg responses. Peripheral induction of Treg is one mechanism by which this balance may be maintained. Thus, it is important to understand factors that influence de novo generation of CD4(+)CD25(+)FOXP3(+) Treg. Here, we focus on the effects of cytokines and the cell cycle inhibitor rapamycin. The cytokines IL-2 and IL-7, but not IL-4, increased initial activation induced FOXP3 expression, increased proliferation and sustained expression of FOXP3(+) cells throughout the culture. Addition of rapamycin to cultures containing IL-2 further increased the frequency and absolute number of functional CD4(+)CD25(+)FOXP3(+) Treg. This increase was not due to selective proliferation of FOXP3 cells, but was instead, the result of an increase in the frequency of FOXP3(+) cells induced in GO through delayed activation while the addition of IL-2 promoted survival and proliferation of the FOXP3(+) population. Thus, combination of raparaycin and IL-2 may provide improved treatment options in transplantation and autoimmunity by promoting induction, survival, and expansion of functional iTreg from CD4(+)CD25(-) cells. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:293 / 302
页数:10
相关论文
共 39 条
[1]   Balancing autoaggressive and protective T cell responses [J].
Abbas, Abul K. ;
Lohr, Jens ;
Knoechel, Birgit .
JOURNAL OF AUTOIMMUNITY, 2007, 28 (2-3) :59-61
[2]   Immunopharmacology of rapamycin [J].
Abraham, RT ;
Wiederrecht, GJ .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :483-510
[3]   IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients [J].
Ahmadzadeh, M ;
Rosenberg, ST .
BLOOD, 2006, 107 (06) :2409-2414
[4]   Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production [J].
Allan, Sarah E. ;
Crome, Sarah Q. ;
Crellin, Natasha K. ;
Passerini, Laura ;
Steiner, Theodore S. ;
Bacchetta, Rosa ;
Roncarolo, Maria G. ;
Levings, Megan K. .
INTERNATIONAL IMMUNOLOGY, 2007, 19 (04) :345-354
[5]   IL-2 receptor alpha deficiency and features of primary biliary cirrhosis [J].
Aoki, Christopher A. ;
Roifman, Chaim M. ;
Lian, Zhe-Xiong ;
Bowlus, Christopher L. ;
Norman, Gary L. ;
Shoenfeld, Yehuda ;
Mackay, Ian R. ;
Gershwin, M. Eric .
JOURNAL OF AUTOIMMUNITY, 2006, 27 (01) :50-53
[6]   Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells [J].
Battaglia, M ;
Stabilini, A ;
Roncarolo, MG .
BLOOD, 2005, 105 (12) :4743-4748
[7]   Tr1 cells: From discovery to their clinical application [J].
Battaglia, M ;
Gregori, S ;
Bacchetta, R ;
Roncarolo, MG .
SEMINARS IN IMMUNOLOGY, 2006, 18 (02) :120-127
[8]   Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance [J].
Battaglia, M ;
Stabilini, A ;
Draghici, E ;
Gregori, S ;
Mocchetti, C ;
Bonifacio, E ;
Roncarolo, MG .
DIABETES, 2006, 55 (01) :40-49
[9]   Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients [J].
Battaglia, Manuela ;
Stabilini, Angela ;
Migliavacca, Barbara ;
Horejs-Hoeck, Jutta ;
Kaupper, Thomas ;
Roncarolo, Maria-Grazia .
JOURNAL OF IMMUNOLOGY, 2006, 177 (12) :8338-8347
[10]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348